BIO-GENE TECHNOLOGY ORD
Bio-Gene Reports Strong Flavocide Results Against Ticks to Leading US Lyme Disease Conference
Bio-Gene Technology (ASX: BGT) has released new data confirming that its lead compound Flavocide delivers strong activity against ticks responsible for spreading Lyme disease in the United States. Presented by Purdue University researchers at the International Conference on Lyme Borreliosis and Other Tick-Borne Diseases in Chicago, the findings showed that Flavocide achieved more than 90% […]
Bio-Gene awarded $3m in US grants to develop insecticides for military use
Bio-Gene Technology (ASX: BGT) has been awarded $3 million in grants by the US Department of Defense to develop insecticide products to protect its workforce from threats posed by disease-carrying species including mosquitoes and ticks. The grants have been provided under the government’s Deployed Warfighter Protection research program. The program aims to identify and test […]
Bio-Gene signs public health control partnership with Clarke Mosquito Control
Just over three months since seeing its insecticide products pass US trials, agriculture technology development company Bio-Gene Technology (ASX: BGT) has unveiled a partnership with US-based Clarke Mosquito Control to develop its Flavocide and Qcide products for use in public health mosquito control in North, South and Central America. Clarke is currently the largest public […]
US trials confirm Bio-Gene’s Flavocide to be an effective control for mosquito-related diseases
The results of collective US trials by Australian ag-tech development company Bio-Gene Technology (ASX: BGT) have confirmed the natural compound product Flavocide can control the Anopheles gambiae mosquito species which carries malaria and is increasingly resistant to commonly-used sprays. Conducted at Purdue University’s world-leading entomology faculty which specialises in vector control, the trials showed that […]